Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Recurrent Aggressive Non-Hodgkin's Lymphoma
NCT00131937Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2005
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate. Started Oct 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00131937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131937.